+

PL1639010T3 - Zastępczy terapeutyczny punkt końcowy (surogat) opartej na anty-ctla-4 immunoterapii choroby - Google Patents

Zastępczy terapeutyczny punkt końcowy (surogat) opartej na anty-ctla-4 immunoterapii choroby

Info

Publication number
PL1639010T3
PL1639010T3 PL04785793T PL04785793T PL1639010T3 PL 1639010 T3 PL1639010 T3 PL 1639010T3 PL 04785793 T PL04785793 T PL 04785793T PL 04785793 T PL04785793 T PL 04785793T PL 1639010 T3 PL1639010 T3 PL 1639010T3
Authority
PL
Poland
Prior art keywords
ctla
disease
based immunotherapy
therapeutic endpoint
surrogate therapeutic
Prior art date
Application number
PL04785793T
Other languages
English (en)
Polish (pl)
Inventor
Israel Lowy
Geoffrey M. Nichol
Original Assignee
E. R. Squibb & Sons, L.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by E. R. Squibb & Sons, L.L.C. filed Critical E. R. Squibb & Sons, L.L.C.
Publication of PL1639010T3 publication Critical patent/PL1639010T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL04785793T 2003-05-30 2004-05-28 Zastępczy terapeutyczny punkt końcowy (surogat) opartej na anty-ctla-4 immunoterapii choroby PL1639010T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47506703P 2003-05-30 2003-05-30
PCT/US2004/016995 WO2005003298A2 (fr) 2003-05-30 2004-05-28 Resultat de l'utilisation d'agents therapeutiques succedanes dans l'immunotherapie a base d'anti-ctla-4
EP04785793.3A EP1639010B1 (fr) 2003-05-30 2004-05-28 Resultat de l'utilisation d'agents therapeutiques succedanes dans l'immunotherapie a base d'anti-ctla-4

Publications (1)

Publication Number Publication Date
PL1639010T3 true PL1639010T3 (pl) 2020-11-30

Family

ID=33563738

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04785793T PL1639010T3 (pl) 2003-05-30 2004-05-28 Zastępczy terapeutyczny punkt końcowy (surogat) opartej na anty-ctla-4 immunoterapii choroby

Country Status (19)

Country Link
US (2) US7465446B2 (fr)
EP (1) EP1639010B1 (fr)
JP (1) JP2007502330A (fr)
CN (1) CN1816567A (fr)
AU (1) AU2004253865B2 (fr)
CA (1) CA2527373A1 (fr)
CY (1) CY1123535T1 (fr)
DK (1) DK1639010T3 (fr)
ES (1) ES2813928T3 (fr)
HU (1) HUE051533T2 (fr)
IL (1) IL172028A (fr)
MX (1) MXPA05012832A (fr)
NO (1) NO344368B1 (fr)
NZ (1) NZ543768A (fr)
PL (1) PL1639010T3 (fr)
PT (1) PT1639010T (fr)
SI (1) SI1639010T1 (fr)
WO (1) WO2005003298A2 (fr)
ZA (1) ZA200510125B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CA2481207C (fr) * 2002-04-12 2015-06-30 Medarex, Inc. Methodes de traitement dans lesquelles sont utilises des anticorps du ctla-4
US7595048B2 (en) 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
US7465446B2 (en) 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
CN103127502A (zh) 2004-05-20 2013-06-05 津莫吉尼蒂克斯公司 使用il-21和单克隆抗体疗法治疗癌症的方法
US7473678B2 (en) * 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
GB0426644D0 (en) * 2004-12-03 2005-01-05 Univ Aberdeen T-cell modulation
SI2439273T1 (sl) 2005-05-09 2019-05-31 Ono Pharmaceutical Co., Ltd. Človeška monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka z uporabo protiteles proti PD-1 samostojno ali v kombinaciji z ostalimi imunoterapevtiki
US7943743B2 (en) 2005-07-01 2011-05-17 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
CA2626859A1 (fr) * 2005-11-08 2007-05-18 Medarex, Inc. Traitement anti-tnf-alpha destine a traiter l'enterocolite associee a un traitement par anticorps therapeutique immunostimulateur
WO2007056539A2 (fr) * 2005-11-08 2007-05-18 Medarex, Inc. Prevention et traitement de l'enterocolite associee a un traitement par anticorps anti-ctla-4
CA2630157C (fr) 2005-12-07 2018-01-09 Medarex, Inc. Regimes d'escalade de dose d'anticorps ctla-4
EP2013348A4 (fr) 2006-03-30 2009-09-02 Univ California Procédés et compositions de secrétion localisée d'anticorps anti-ctla-4
US7919079B2 (en) * 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
US20100099090A1 (en) * 2007-03-05 2010-04-22 Bristol-Mayers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
US8119129B2 (en) * 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
WO2010042433A1 (fr) * 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combinaison d'anticorps cd137 et d'anticorps ctla-4 pour le traitement de maladies prolifératives
JP5589077B2 (ja) * 2009-07-20 2014-09-10 ブリストル−マイヤーズ スクイブ カンパニー 増殖性疾患の相乗的処置のための抗ｃｔｌａ４抗体と多様な治療レジメンとの組み合わせ
EP2488553B1 (fr) * 2009-10-12 2015-06-17 Pfizer Inc. Traitement d'un cancer
GB0920258D0 (en) * 2009-11-19 2010-01-06 Alligator Bioscience Ab New medical agents and use thereof
US8778618B2 (en) 2010-04-16 2014-07-15 The Johns Hopkins University Compositions and methods for characterizing a myopathy
JP6074435B2 (ja) 2011-10-26 2017-02-01 ナショナル キャンサー センター 変異ｃｔｌａ４遺伝子移入ｔ細胞及びこれを含む抗がん免疫治療用組成物
WO2013169971A1 (fr) 2012-05-10 2013-11-14 Bristol-Myers Squibb Company Anticorps antitumoraux à titre de biomarqueurs prédictifs ou pronostiques de l'efficacité et de la survie chez les patients traités à l'ipilimumab
RS61678B1 (sr) 2014-05-28 2021-05-31 Agenus Inc Anti-gitr antitela i postupci za njihovu primenu
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
LT3303394T (lt) 2015-05-29 2020-10-12 Agenus Inc. Anti-ctla-4 antikūnai ir jų naudojimo būdai
BR112018000903A2 (pt) 2015-07-16 2018-09-11 Biokine Therapeutics Ltd. composições e métodos para o tratamento de câncer
JP7089470B2 (ja) 2015-12-02 2022-06-22 アジェナス インコーポレイテッド 抗体およびその使用方法
WO2018035710A1 (fr) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anticorps anti-ctla4
WO2018077385A1 (fr) * 2016-10-25 2018-05-03 Biontech Rna Pharmaceuticals Gmbh Détermination de doses d'agents immunothérapeutiques
EP4289484A3 (fr) 2016-12-07 2024-03-06 Agenus Inc. Anticorps anti-ctla-4 et leurs procédés d'utilisation
KR20190124256A (ko) 2017-02-28 2019-11-04 브리스톨-마이어스 스큅 컴퍼니 백신에 대한 면역 반응을 증진시키기 위한 증진된 adcc를 갖는 항-ctla-4 항체의 용도
US11643463B2 (en) 2017-05-19 2023-05-09 Wuxi Biologics (Shanghai) Co., Ltd. Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
CA3102334A1 (fr) 2018-06-15 2019-12-19 Mina Therapeutics Limited Polytherapies comprenant un arnca alpha c/ebp
US20210317461A1 (en) 2018-08-09 2021-10-14 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
IL287801A (en) * 2019-05-07 2022-07-01 Immunicom Inc Increasing responses to checkpoint inhibitors by extracorporeal apheresis
EP4329777A1 (fr) 2021-04-28 2024-03-06 MiNA Therapeutics Limited Polythérapies comprenant c/ebp alpha arnsa
WO2024212152A1 (fr) * 2023-04-13 2024-10-17 Adagene Pte. Ltd. Anticorps anti-ctla4 et leurs procédés de fabrication et d'utilisation
WO2025052098A1 (fr) 2023-09-08 2025-03-13 Mina Therapeutics Limited Compositions de petits arn activateurs (sarna) ciblant tmem173 et procédés d'utilisation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
EP1141028B1 (fr) 1998-12-23 2010-02-17 Pfizer Inc. Anticorps monoclonaux humains diriges contre l'antigene ctla-4
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
KR20020047132A (ko) 1999-08-24 2002-06-21 메다렉스, 인코포레이티드 인간 씨티엘에이-4 항체 및 그의 용도
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
AU2001233027A1 (en) 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
IL149701A0 (en) 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
CA2481207C (fr) 2002-04-12 2015-06-30 Medarex, Inc. Methodes de traitement dans lesquelles sont utilises des anticorps du ctla-4
US7465446B2 (en) 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
CA2630157C (fr) 2005-12-07 2018-01-09 Medarex, Inc. Regimes d'escalade de dose d'anticorps ctla-4

Also Published As

Publication number Publication date
CA2527373A1 (fr) 2005-01-13
SI1639010T1 (sl) 2020-10-30
EP1639010B1 (fr) 2020-06-10
US7744875B2 (en) 2010-06-29
US20090074752A1 (en) 2009-03-19
ES2813928T3 (es) 2021-03-25
US7465446B2 (en) 2008-12-16
WO2005003298A3 (fr) 2005-06-23
HUE051533T2 (hu) 2021-03-01
CN1816567A (zh) 2006-08-09
NZ543768A (en) 2009-07-31
CY1123535T1 (el) 2022-03-24
DK1639010T3 (da) 2020-09-07
NO344368B1 (no) 2019-11-18
AU2004253865B2 (en) 2011-06-23
MXPA05012832A (es) 2006-02-13
AU2004253865A1 (en) 2005-01-13
ZA200510125B (en) 2006-12-27
EP1639010A2 (fr) 2006-03-29
US20040241169A1 (en) 2004-12-02
JP2007502330A (ja) 2007-02-08
IL172028A (en) 2012-01-31
PT1639010T (pt) 2020-09-04
EP1639010A4 (fr) 2006-08-09
NO20056027L (no) 2006-02-20
WO2005003298A2 (fr) 2005-01-13

Similar Documents

Publication Publication Date Title
PL1639010T3 (pl) Zastępczy terapeutyczny punkt końcowy (surogat) opartej na anty-ctla-4 immunoterapii choroby
IL175935A0 (en) Solid forms of anti-egfr antibodies
IL177602A0 (en) Uses of anti-ctla-4 antibodies
IL227841A0 (en) Dihydropyridinones for the treatment of cancer
HK1096083A1 (en) Sulfonamide derivatives for the treatment of diseases
EP1745573A4 (fr) Procedes de fabrication de 2-desoxy-beta-l-nucleosides
SI1587542T1 (sl) Uporaba anti-cd100 protiteles
GB0421525D0 (en) Inhibitors of protein kineses
AP2006003669A0 (en) Sulfonamide derivatives for the treatment of diseases
GB0329874D0 (en) Compounds useful for the treatment of diseases
GB0305150D0 (en) Use of therapeutic compounds
EP1611120A4 (fr) Nouvelles m thodes de traitement des maladies inflammatoires
IL172972A0 (en) Compositions and methods for immunotherapy of cancer and infectious diseases
HK1155670A1 (en) Therapeutic use of anti-cs1 antibodies
GB0325624D0 (en) Use of microparticles for antigen delivery
GB0322963D0 (en) Methods of controlling reducant addition
GB0400802D0 (en) Compounds for the treatment of disease
AU152108S (en) Set of pavers
ZA200606780B (en) Compounds for the treatment of diseases
IL175611A0 (en) Combinations for the treatment of proliferative diseases
AP2006003743A0 (en) Compounds useful for the treatment of diseases
GB0425064D0 (en) Compounds useful for the treatment of diseases
GB0420867D0 (en) Compounds for the treatment of diseases
IL177531A0 (en) Compounds for the treatment of diseases
GB0425073D0 (en) Compounds for the treatment of diseases
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载